See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: May 11, 2006

Insomnia Breast Cancer Allergy

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:


CNS Healthcare in Jacksonville, Fla., is conducting a research study of an investigational medication for adults 65 or older who are having difficulty falling asleep or staying asleep.

Qualified participants will receive study-related medical care and study-related medication at no charge, as well as compensation for time and travel. There is no overnight stay.

The research site is in Jacksonville, Fla.

More information

Please see


Breast Cancer

The primary purpose of this trial is to determine if an investigational drug is able to reduce advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.

Participants should be male or female volunteers at least 18-years-old who have a diagnosis of breast cancer that is now metastatic (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that can't be removed by surgery.

The research site is in Coeur d'Alene, Idaho.

More information

Please see



This study is evaluating the safety and efficacy of an investigational medication in people with fall allergies to ragweed.

Successful candidates for this research should be between the ages of 18 and 55 who have a history of fall allergies, such as ragweed, that required treatment with antihistamines or nasal steroids in the past and are in good general health.

The research site is in St. Louis, Mo.

More information

Please see


Copyright 2006 CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.